Latest Impairment News

Central Petroleum has amended its sub-salt exploration permit sale, excluding the EP82 permit and retaining Helium Australia Pty Ltd, while anticipating a $4.2 million impairment charge in FY26.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

Locality Planning Energy Holdings has reached a confidential settlement over its Harbour Towers dispute, anticipating a net gain and cash inflow in FY2026. This resolution reverses prior impairment losses and signals a positive financial turn for the embedded energy provider.

Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Bapcor Limited has revised its first-half FY26 guidance to a statutory net loss, citing weaker trade segment performance and one-off costs, while maintaining a cautiously optimistic full-year outlook supported by cost savings and leadership changes.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Collins Foods Limited reported solid half-year growth with revenue up 6.6% and net profit rising 12.7%, driven by strong performance in its KFC operations across Australia and Europe. The company declared a fully franked interim dividend of 13 cents per share, while navigating increased provisions linked to wage compliance and ongoing class action litigation.

Treasury Wine Estates signals a major non-cash impairment on its US assets, expected to wipe out all goodwill in the Americas segment amid softer market growth assumptions.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

Excite Technology Services Limited reported a remarkable 370% revenue increase to $13.54 million for H1 FY2026, driven by strong growth across its cybersecurity, digital forensics, and IT managed services divisions. However, losses widened 43% to $2.51 million, reflecting restructuring and scaling costs, while the company secured $2.1 million in convertible notes to support its growth ambitions.